A retrospective propensity-matched study on the efficacy and safety of tripterygium glycosides as the adjuvant treatment for patients with lupus nephritis
10.3760/cma.j.cn141217-20240702-00203
- VernacularTitle:雷公藤多苷辅助治疗狼疮肾炎疗效和安全性的回顾性倾向匹配研究
- Author:
Qingfeng ZHANG
1
;
Ye JI
;
Xuebing FENG
Author Information
1. 南京大学医学院附属鼓楼医院风湿免疫科，南京 210008
- Publication Type:Journal Article
- Keywords:
Lupus nephritis;
Treatment outcome;
Retrospective studies;
Tripterygium wilfordi polyglucoside
- From:
Chinese Journal of Rheumatology
2025;29(8):645-654
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of tripterygium glycosides (TG) in the adjuvant treatment for patients with lupus nephritis(LN).Methods:A retrospective propensity-matched study was conducted using data collected from LN inpatients who addmitted to nanjing Drum Hospital between January 2010 and June 2022. Patients were divided into TG-treated and non-TG-treated groups according to whether or not they were treated with TG or not in a 1∶2 ratio. Univariate and multivariate analyses corrected for confounders were performed using binary logistic regression models, and odds ratios ( OR) and corresponding 95% confidence intervals ( CI) were calculated. Results:A total of 177 patients with active LN were included, 59 in TG-treated group and 118 in non-TG-treated group, and the baseline data and other medications used in the trial were roughly comparable in both groups. In the TG treatment group, complete remission (CR) and partial remission (PR) patients accounted for 37.3% (22 cases) and 55.9% (33 cases), respectively. Concomitant treatment with TG was contributed to the achievement of CR [an adjusted OR(95% CI) 2.95 (1.27, 6.87), P=0.012]. The doses of TG ≥40 mg/d and treatment for 12 to 42 weeks were associated with improved CR [ OR(95% CI)=2.94(1.16,7.45), P=0.023; adjusted OR(95% CI)=3.42(1.21,9.63), P=0.020 respectively]. In addition, the combination of TG and hydroxychloroquine improved patients′ CR rates compared with monotherapy, no additive interactions between TG and immunosuppressive drugs were found. Concomitant treatment with TG did not cause additional safety concerns. Conclusion:Adjuvant therapy with TG can effectively and safely improve LN remission.
